Follow us on Twitter
This page is updated frequently with new Roti-related patent applications. Subscribe to the Roti RSS feed to automatically get the update: related Roti RSS feeds. RSS updates for this page: Roti RSS
|| List of recent Roti-related patents
|Alpha helix mimetic compositions for treating cancer and other cbp/catenin-mediated diseases and conditions|
Alpha-helix mimetic structures and compounds represented by the formula (i) wherein the general formula and the definition of each symbol are as defined in the specification, a compound relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed..
|Cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes as v1a antagonists|
The present invention provides 4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes, which act as v1a receptor modulators, and in particular as v1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior..
|Methods for rapidly treating severe hypoglycemia|
Disclosed is a method for treating or preventing hypoglycemia in a patient comprising administering an effective amount of a composition comprising a glucagon peptide which has been dried in a non-volatile buffer, and wherein the glucagon peptide has a ph memory that is about equal to the ph of the glucagon peptide in the non-volatile buffer, and an aprotic polar solvent, wherein the moisture content of the formulation is less than 5%, and wherein the dried glucagon peptide maintains the ph memory that is about equal to the ph of the glucagon peptide in the non-volatile buffer when the dried glucagon peptide is reconstituted in the aprotic polar solvent, wherein the patient has been diagnosed as having a blood glucose level between 0 mg/dl and less than 50 mg/dl or has an indication of impending hypoglycemia based on a blood glucose monitoring device before administration of the composition, and wherein the patient has a blood glucose level greater than 50 mg/dl to 180 mg/dl within 1 to 20 minutes after administration of the composition.. .
|System and method for delivering protease inhibitors|
The disclosed invention provides a system and method of artificially retarding fibrin-based blood clot degradation via the sustained release of a protease inhibitor, such as, for example, aprotinin or tranexamic acid (“ta”). The sustained release of the protease inhibitor is accomplished through incorporation within a biodegradable polymer microsphere to produce a protease inhibitor formulation.
|Metal sensitive mutants of matrix metalloproteases and uses thereof|
Provided herein are methods of using modified matrix metalloprotease (mmp) enzymes that exhibit regulated activity in the presence of calcium. The methods include conditionally controlling the activity of the mmps through the use of calcium to treat fibrotic diseases or conditions involving a component of the extracellular matrix (ecm)..
|Plaque array methods and compositions for forming and detecting plaques|
Provided herein are methods and compositions for the in vitro formation of an array of plaque particles for use in biological assays, diagnosis, drug discovery and drug development. More specifically, the embodiments described herein relate to the in vitro synthesis of plaque particles when treated with biofluids and identification of such plaque particles by a variety of detection systems.
|Optical capsule and spectroscopic method for treating and diagnosing the intestinal tract|
A device and method for mapping, diagnosing and treating disorders or other diseases, disorders or conditions (e.g., bleeding, ischemic or necrotic tissue, and presence of certain chemicals or substances) of the intestinal tract is provided using a capsule passing through the intestinal tract and sensing optical characteristics as the capsule passes through. Further, a capsule tracking system is provided for tracking a capsule's location along the length of an intestinal tract as various treatment and/or sensing modalities are employed.
|Methods and pomegranate extract composition for treating diabetes related atherosclerotic complications in humans|
One or more embodiments of the invention are directed to methods of using pomegranate extracts for treating diabetes related atherosclerotic complications in humans. The methods comprise the step of administering to the patients a composition comprising a therapeutically effective amount of an extract from pomegranate..
|Method for detection of characteristics of organ fibrosis|
The disclosed invention is a method for detecting indications of the presence of liver disease and other fibrotic diseases using a magnetic-resonance based technique for measuring fine tissue and bone textures. Specifically, the invention focuses on adaptations to this prior art to facilitate assessment of the presence and severity of liver disease, lung disease, and other fibrotic disease by measuring spatial wavelengths characteristic of the specific disease process across an areal cross-section through an organ.
|Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases|
The present methods and compositions are of use for treatment of conditions involving fibrosis, such as peyronie's disease plaque, penile corporal fibrosis, penile veno-occlusive dysfunction, dupuytren's disease nodules, vaginal fibrosis, clitoral fibrosis, female sexual arousal disorder, abnormal wound healing, keloid formation, general fibrosis of the kidney, bladder, prostate, skin, liver, lung, heart, intestines or any other localized or generalized fibrotic condition, vascular fibrosis, arterial intima hyperplasia, atherosclerosis, arteriosclerosis, restenosis, cardiac hypertrophy, hypertension or any condition characterized by excessive fibroblast or smooth muscle cell proliferation or deposition of collagen and extracellular matrix in the blood vessels and/or heart. In certain embodiments, the compositions may comprise a pde-4 inhibitor, a pde-5 inhibitor, a compound that elevates cgmp and/or pkg, a stimulator of guanylyl cyclase and/or pkg, a combination of a compound that elevates cgmp, pkg or no with an antioxidant that decreases ros, or a compound that increases mmp activity..
|Antagonists of cb1 receptor|
The invention relates to an antagonist of cb1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.. .
|5,6,7,8-tetrahydro-6-[n,n-bis[(2-thienyl)ethyl]] amino-1-naphthol, and preparing method and use thereof|
The present disclosure relates to 5,6,7,8-tetrahydro-6-[n,n-bis[(2-thienypethyl]]amino-1-naphthol, a method for preparing the same, and use of 5,6,7,8-tetrahydro-6-[n,n-bis[(2-thienypethyl]]amino-1-naphthol as a reference compound for determining an impurity in rotigotine or a preparation thereof.. .
|Device and method for tacking plaque to blood vessel wall|
A tack device for holding plaque against blood vessel walls in treating atherosclerotic occlusive disease can be formed as a thin, annular band of durable, flexible material. The tack device may also have a plurality of barbs or anchoring points on its outer annular periphery.
|Methods for treatment of nephrotic syndrome and related conditions|
The present disclosure provides a method for treating and/or preventing nephrotic syndrome, such as but not limited to minimal change disease and membranous nephropathy, and conditions related to nephrotic syndrome, such as but not limited to, proteinuria and edema, as well as diabetic nephropathy, diabetes mellitus, lupus nephritis or primary glomerular disease. The present disclosure further provides methods for reducing proteinuria and other disease states as discussed herein.
|Novel apoc-i isoforms and their use as biomarkers and risk factors of atherosclerotic disease|
Novel isoforms of apolipoprotein c-i (apoc-i), namely apolipoprotein c-i1 (apoc-i1) and apolipoprotein c-i1′ (apoc-i1′), both of which have a molecular weight of approximately 90 daltons greater than native apolipoprotein c-i (seq id no:6) and native apolipoprotein c-i′ (seq id no:7), are shown to be both biomarkers for diagnosing atherosclerotic disease as well as risk factors for subjects having increased risk of developing an atherosclerotic disease.. .
|Modulation of angiopoietin-like 3 expression|
Provided herein are methods, compounds, and compositions for reducing expression of an angptl3 mrna and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing plasma lipids, plasma glucose and atherosclerotic plaques in an animal.
|Anti-pdgfr-beta antibodies and uses thereof|
The present invention provides antibodies that bind to platelet derived growth factor receptor beta (pdgfr-beta) and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human pdgfr-beta with high affinity.
|Method and system for determining whether arterial tissue comprises atherosclerotic plaque|
Provided herein are methods and systems to determine at least one mechanical property of a tissue sample and, based upon the determined at least one mechanical property, whether the tissue sample comprises atherosclerotic plaque. The method comprises generating a shear wave in an arterial tissue sample by applying an acoustic impulse thereto; measuring propagation of the shear wave via an optical coherence elastography apparatus; determining at least one mechanical property of the arterial tissue sample based on the propagation of the shear wave; and comparing the at least one mechanical property of the arterial tissue sample to a reference data set to determine whether the arterial tissue sample comprises atherosclerotic plaque.
|Diphenyl ether compounds for the treatment of liver, lung disorders, diabetic complications and cardiovascular diseases|
Described herein are compounds of formula (i), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof, for use in treating liver diseases such as non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash), and other fibrotic diseases of the liver; diabetic complications such as macro (ischemic heart disease, cerebrovascular disease and peripheral vascular disease) and micro (cataract, retinopathy nephropathy neuropathy, maculopathy and glaucoma) vascular complication; and cardiovascular diseases such as atherosclerosis, restenosis, hypertension, vasospasm, and cardiac hypertrophy; and lung disorders and lung fibrosis.. .
|Combination therapy in treatment of oncological and fibrotic diseases|
The invention relates to new methods for the treatment of oncological and fibrotic disease comprising the combined administration of an inhibitor of vascular endothelial growth factor receptors (vegfrs) in conjunction with a thrombin inhibitor.. .
|Method for diagnosing whether a subject is at high risk for developing atherosclerotic vascular disease|
A method for diagnosing whether a subject is at high risk for developing atherosclerotic vascular disease (asvd) is provided. The method comprises the following steps: (1) providing a specimen from a subject; (2) analyzing the specimen by using a gradient gel electrophoresis analysis; and (3) based on the result of the gel electrophoresis analysis in step (2), determining if the subject is at high risk for developing atherosclerotic vascular disease..
|Electrostimulation in treating cerebrovascular conditions|
A system for treating a medical condition in a living body, comprising two subsystems, an implant subsystem and an electrical stimulation unit subsystem. The implant subsystem comprises at least one electrostimulation module, contains at least one electrically conductive electrode and, preferably, an anchoring member.
|Tuned rf energy and electrical tissue characterization for selective treatment of target tissues|
A catheter and catheter system can use energy tailored for remodeling and/or removal of target material along a body lumen, often of atherosclerotic material of a blood vessel of a patient. An elongate flexible catheter body with a radially expandable structure may have a plurality of electrodes or other electrosurgical energy delivery surfaces to radially engage atherosclerotic material when the structure expands.
|Apoptosis signal-regulating kinase inhibitors|
Wherein variables are as defined above. The compounds have apoptosis signal-regulating kinase (“ask1”) inhibitory activity, and are thus useful in the treatment of ask1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases, diabetes, diabetic nephropathy, cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases, copd, idiopathic pulmonary fibrosis, acute lung injury, acute and chronic liver diseases, and neurodegenerative diseases..
|Diagnosis, prevention and treatment of disorders characterized by undesirable cell proliferation|
The present invention relates to compositions and methods for the reduction of atherosclerotic plaques and the decrease in the level of total serum cholesterol, triglycerides, serum ldl cholesterol, and serum hdl cholesterol. The present invention also relates to methods for the diagnosis, prevention and treatment of atherosclerosis and mycoplasma associated diseases, cardiotoxicity related to cancer treatment, and chagas disease related cardiomyopathies..
|Use of neuregulin-4 for treatment of inflammatory bowel disease and necrotizing enterocolitis|
The invention provides methods, pharmaceutical compositions and kits for treating, inhibiting and/or reducing the severity of inflammatory bowel disease and necrotizing enterocolitis in a subject in need thereof by administering an effective amount of a composition comprising an activator of erbb4.. .
|System for facilitating transcatheter aortic valve procedures using femoral access|
A device for facilitating use of instruments disposed through an aortic arch includes an embolic deflector having a first surface positionable in contact with a wall of an aortic arch such that a porous barrier portion of the embolic deflector covers ostia of at least the brachiocephalic and left common carotid arteries. A second surface is disposed on an opposite face from the first surface.
|Biomarker for coronary artery disease|
In various embodiments methods are provided for identifying a mammal having an elevated risk for an adverse cardiac event (e.g. An mi) and/or determining the prognosis for the mammal.
|Urine biomarkers for necrotizing enterocolitis and sepsis|
Aspects of the invention include methods, compositions, and kits for diagnosing necrotizing enterocolitis (nec), for diagnosing sepsis, for providing a prognosis for a patient with nec, and for predicting responsiveness of a patient with nec to medical intervention. These methods find use in a number of applications, such as diagnosing and treating infants who are suspected of having nec, intestinal perforation (ip), or sepsis..
|Probe for detecting dead cell|
Provided is a molecular imaging probe that accumulates specifically and highly sensitively at a tumor site in vivo, and enables quantitative analysis, e.g. A probe for detecting an apoptotic cell(s) and/or a necrotic cell(s), comprising a fusion protein of a tim4 protein and a protein or polypeptide that forms a dimer, the protein or polypeptide being bound to the c-terminus of the tim4 protein, wherein the mucin domain of the tim4 protein and the c-terminal side domain thereof are replaced with a polypeptide consisting of the amino acid sequence of a) or b) below: a) an amino acid sequence having a length of 30 to 120 amino acid residues comprised in the amino acid sequence of the mucin domain of a wild-type tim4 protein; b) an amino acid sequence having an identity of not less than 80% to the amino acid sequence of a)..
|Multistage nanoparticle drug delivery system for the treatment of solid tumors|
Nanoparticles for a selective, two stage delivery to tumors have been developed. The nanoparticles are initially sized so that they preferentially accumulate in the tumor tissue as a result of leakage through the defective vascular in the solid tumors.
|Biomarker-targeting contrast agents and their use in magnetic resonance imaging for detection of atherosclerotic plaque|
A composition comprising: a liposome having a bilayer structure, a gadofullerene having a high relaxivity, and an amphiphilic receptor ligand. In the composition, the gadofullerene is embedded in the bilayer structure of the liposome.
|Method of destroying tissue cells by electroporation|
An apparatus and method for performing non-invasive treatment of the human face and body by electroporation in lieu of cosmetic surgery is provided. The apparatus comprises a high voltage pulse generator and an applicator having two or more electrodes in close mechanical and electrical contact with the patient's skin for applying the pulses to the patient's skin.
|Methods for identifying stem cells based on nuclear morphotypes|
Methods for identifying stem cells and other cells specific to embryogenesis and carcinogenesis, classifying tissue samples, diagnosing precancerous and cancerous or atherosclerotic lesions, testing the value of anticancer agents, discovering macromolecules specifically expressed in particular cell types, using stem cells in restorative tissue therapy as well as methods for preparing tissue samples so heteromorphic nuclear morphotypes remain intact are disclosed.. .
|Novel compounds as diacylglycerol acyltransferase inhibitors|
This invention relates to novel compounds which are inhibitors of acyl coenzyme a: diacylglycerol acyltransferase 1 (dgat-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to dgat-1 dysfunction or where modulation of dgat-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, genetic (type 1, type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, excess hair growth (including syndromes associated with hirsutism), nephrotic syndrome, fibrosis such as myocardial, renal and liver fibrosis, hepatitis c virus infection and acne or other skin disorders.. .
|Magnesium battery electrolyte|
A magnesium battery electrolyte with a wide electrochemical window was developed. The electrolyte includes an organic boron magnesium salt and an aprotic polar solvent.
|Regression of arterial plaque|
Some embodiments of the present invention provide pharmaceutical formulations, for treating atherosclerosis in a mammal, including a bile acid and/or a terpene atherosclerotic plaque emulsifier. Some embodiments provide methods for administering such pharmaceutical formulations.
|Use of secretor, lewis and sialyl antigen levels in clinical samples as predictors of risk for disease|
An individual at risk for necrotizing enterocolitis and related disorders can be identified by measuring the level of at least one secretor antigen in a biological sample from the individual and comparing the measured level of the at least one secretor antigen to a predetermined value or a predetermined range of values. Among the secretor antigens which can be measured are: the h-1, h-2, lewisb and lewisy antigens and derivatives thereof (e.g., a sialylated form of lewis a, lewis x, lewis b, lewis y; h-1, h-2, lewis a, lewis x, lewis b or lewis y)..
|Tin-117m somatostatin receptor binding compounds and methods|
Tin-117m somatoostatin analogues or antagonist are used to treat tumors and symptoms associated with these tumors which express somatostatin receptors, such as gastroenteropancreatic neuroendocrine tumors. The tin-117m somatostatin receptor binding compounds can be administered at a dosage which is effectively apoptotic and not necrotic.
|Methods, systems, and media for determining carotid intima-media thickness|
Methods, systems, and media for determining carotid intima-media thickness are provided. In some embodiments, a method for determining carotid intima-media thickness of a carotid artery is provided, the method comprising: receiving a frame from a plurality of images, wherein each of the plurality of images includes a portion of the carotid artery; receiving a user selection of a location with the frame; setting a region of interest, based on the received user selection; detecting a first border and a second border within the region of interest; applying one or more active contour models to the first border and the second border to generate a smoothed first border and a smoothed second border; and calculating the intima-media thickness based at least in part on the smoothed first border and the second smoothed border..
|Methods for the treatment of sialorrhea|
The present invention provides safe and effective methods for the treatment of sialorrhea (excessive drooling) by administering an effective amount of n-desethyloxybutynin, or an optical r- or s-isomer thereof. N-desethyloxybutynin is a metabolite of oxybutynin and has higher affinity for receptors present in the parotid glands (the salivary glands in humans) than oxybutynin..
|Noninvasive cooling device|
A device (1) for selectively cooling the brain of a warm-blooded animal, in particular a human being, in a noninvasive manner, includes connectable self-contained cooling elements (4, 18, 19) and fixing elements for fixing in the head/neck area of the warm-blooded animal. The cooling device lowers the brain temperature in warm-blooded animals in a quicker and more effective manner without the need for especially trained medical personnel.
|Method for monitoring physiological cycles of a patient to optimize patient therapy|
Physiological parameters of a patient can be used to monitor patient status and/or in conjunction with patient therapy. Physiological cycles may be monitored by implanting a monitoring system into the patient, the system including an implantable pulse generator operably connected to a lead implanted on a carotid sinus of the patient, measuring at least one signal indicative of a physiological parameter of the patient along at least two vectors selected from: a first vector defined between a first electrode of the lead and a second electrode of the lead, a second vector defined between the first electrode of the lead and an electrode integrated into an implantable pulse generator, and a third vector defined between the second electrode of the lead and the electrode integrated into the implantable pulse generator, and providing an output indicative of the at least one signal indicative of the physiological parameter..
|Medicaments for the treatment or prevention of fibrotic diseases|
R1 to r6 and x are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.. .
Methods and compositions for detecting, treating, characterizing, and diagnosing interstitial lung and/or fibrotic diseases are described.. .
|Controlled high efficiency lesion formation using high intensity ultrasound|
An ultrasound system used for both imaging and delivery high intensity ultrasound energy therapy to treatment sites and a method for treating tumors and other undesired tissue within a patient's body with an ultrasound device. The ultrasound device has an ultrasound transducer array disposed on a distal end of an elongate, relatively thin shaft.
|System and methodology for analyzing low-density lipoprotein transport within a multi-layered arterial wall|
Low-density lipoprotein (ldl) transport while incorporating the thickening of the arterial wall and cholesterol lipid accumulation can be analyzed. A multi-layered model can be adopted to represent the heterogeneity using the darcy-brinkman and staverman filtration equations to describe transport within the porous layers of the wall.
|Gay male undergarment|
This invention is an undergarment that embraces the gay male lifestyle by promoting safe sex in a provocatively expressive manner. This garment is unique in several respects.
|Preventing and/or treating cardiovascular disease and/or associated heart failure|
Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) drug induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the heart, and the central and peripheral nervous systems, (iv) plaque rupture of atheromatous lesions of major blood vessels such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the fermoral arteries and the popliteal arteries, (v) diabetes or the complications of diabetes.. .
|Locally-active anticoagulants and anti-inflammatory agents|
A locally-activatable bivalent thrombin binding agent is provided having two thrombin binding moieties for non-overlapping sites on a surface of thrombin linked together by a linker. The linker is a polypeptide having 5 to 30 amino acid residues existing in a folded state under an environmental condition where the binding agent is inactive.
|Electrophysiology catheter for mapping and/or ablation|
The present invention encompasses apparatus and methods for mapping electrical activity within the heart. The present invention also encompasses methods and apparatus for creating lesions in the heart tissue (ablating) to create a region of necrotic tissue which serves to disable the propagation of errant electrical impulses caused by an arrhythmia..
|Special opening aortic embolic protection device for structural heart procedures|
A medical device may include an embolic protection device including a distal filter element, a proximal filter element, and a deflector element disposed between and spacing apart the distal filter element and the proximal filter element. An embolic protection device may include a longitudinally-oriented mouth extending from the distal filter element to the proximal filter element.
Popular terms: [SEARCH]
Follow us on Twitter
This listing is a sample listing of patent applications related to Roti for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Roti with additional patents listed. Browse our RSS directory or Search for other possible listings.